Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1655803

registered interest
date	01/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Vaccination: Manufacturing Industries
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to A review of the Vaccine Taskforce, published by his Department on 29 August 2023, what additional vaccine production capacity, of any type, has been secured as a result of the investments made (a) by the Vaccine Taskforce and (b) subsequently by the Office for Life Sciences, as described in the report.
tabling member constituency	Warley
tabling member printed	John Spellar
uin	195638
answer	answer is ministerial correction date of answer 08/09/2023 answer text <p>Through the Vaccine Taskforce, over £405 million was invested in the United Kingdom’s vaccine manufacturing capabilities across several modalities, to ensure a robust response to COVID-19 and future health emergencies. In December 2022 the Government signed a ten-year strategic partnership with Moderna which will have the capacity to produce up to 250 million cutting-edge mRNA vaccines per year onshore in the event of a pandemic. In May this year, the Government announced a Biomanufacturing Fund, worth up to £38 million, to incentivise investment in commercial-scale vaccines and biotherapeutics manufacturing.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 08/09/2023 14:12:09 answering member 4492 label Biography information for Maria Caulfield
tabling member	318 label Biography information for John Spellar

1655804

registered interest
date	01/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Vaccination: Manufacturing Industries
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to his Department’s paper A review of the Vaccine Taskforce, published on 29 August 2023, what funds the Office for Life Sciences has to invest in additional vaccine production capacity in the UK in order to achieve the onshoring programme objective set for the Vaccines Taskforce.
tabling member constituency	Warley
tabling member printed	John Spellar
uin	195639
answer	answer is ministerial correction date of answer 08/09/2023 answer text <p>Through the Vaccine Taskforce, over £405 million was invested in the United Kingdom’s vaccine manufacturing capabilities across several modalities, to ensure a robust response to COVID-19 and future health emergencies. In December 2022 the Government signed a ten-year strategic partnership with Moderna which will have the capacity to produce up to 250 million cutting-edge mRNA vaccines per year onshore in the event of a pandemic. In May this year, the Government announced a Biomanufacturing Fund, worth up to £38 million, to incentivise investment in commercial-scale vaccines and biotherapeutics manufacturing.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 08/09/2023 14:13:16 answering member 4492 label Biography information for Maria Caulfield
tabling member	318 label Biography information for John Spellar